Association of kinase gene expression signatures, JAK mutations, and IKAROS/IKZF1 deletions with the three risk groups defined by the combined gene expression classifier for RFS and flow cytometric measures of MRD
| Genetic feature . | Combined risk group . | Total . | P (Fisher exact) . | ||
|---|---|---|---|---|---|
| Low . | Intermediate . | High . | |||
| Kinase signature | |||||
| Yes | 0 | 13 (16%) | 22 (58%) | 35 (18%) | < .001 |
| No | 72 (100%) | 68 (84%) | 16 (42%) | 156 (82%) | |
| Total | 72 (100%) | 81 (100%) | 38 (100%) | 191 (100%) | |
| JAK1/JAK2 mutation | |||||
| Yes | 0 | 9 (12%) | 9 (24%) | 18 (10%) | < .001 |
| No | 69 (100%) | 67 (88%) | 28 (76%) | 164 (90%) | |
| Total | 69 (100%) | 76 (100%) | 37 (100%) | 182 (100%) | |
| IKAROS/IKZF1 deletion | |||||
| Yes | 9 (13%) | 20 (26%) | 25 (68%) | 54 (30%) | < .001 |
| No | 60 (87%) | 56 (74%) | 12 (32%) | 128 (70%) | |
| Total | 69 (100%) | 76 (100%) | 37 (100%) | 182 (100%) | |
| Genetic feature . | Combined risk group . | Total . | P (Fisher exact) . | ||
|---|---|---|---|---|---|
| Low . | Intermediate . | High . | |||
| Kinase signature | |||||
| Yes | 0 | 13 (16%) | 22 (58%) | 35 (18%) | < .001 |
| No | 72 (100%) | 68 (84%) | 16 (42%) | 156 (82%) | |
| Total | 72 (100%) | 81 (100%) | 38 (100%) | 191 (100%) | |
| JAK1/JAK2 mutation | |||||
| Yes | 0 | 9 (12%) | 9 (24%) | 18 (10%) | < .001 |
| No | 69 (100%) | 67 (88%) | 28 (76%) | 164 (90%) | |
| Total | 69 (100%) | 76 (100%) | 37 (100%) | 182 (100%) | |
| IKAROS/IKZF1 deletion | |||||
| Yes | 9 (13%) | 20 (26%) | 25 (68%) | 54 (30%) | < .001 |
| No | 60 (87%) | 56 (74%) | 12 (32%) | 128 (70%) | |
| Total | 69 (100%) | 76 (100%) | 37 (100%) | 182 (100%) | |
The gene expression classifier for RFS used in this analysis is the initial classifier developed with 42 probe sets (38 unique genes) provided in supplemental Table 4.